| 11/16/2026 8:28 AM | Unicycive Therapeutics (1766140) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/16/2026 7:00 AM | Unicycive Therapeutics (1766140) Subject Vivo Opportunity Fund Holdings, L.P. (1930214) Filed by | Form SCHEDULE 13G/A | |
| 11/16/2026 5:31 AM | Unicycive Therapeutics (1766140) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/29/2026 3:30 PM | Manning Meredith (1752631) Reporting Unicycive Therapeutics (1766140) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/29/2026 6:46 AM | Unicycive Therapeutics (1766140) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/28/2026 3:31 PM | Unicycive Therapeutics (1766140) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/14/2026 3:15 PM | Unicycive Therapeutics (1766140) Subject Vivo Opportunity Fund Holdings, L.P. (1930214) Filed by | Form SCHEDULE 13G/A | |
| 08/12/2026 7:04 AM | Unicycive Therapeutics (1766140) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/12/2026 5:30 AM | Unicycive Therapeutics (1766140) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/30/2026 10:18 AM | BlackRock, Inc. (2012383) Filed by Unicycive Therapeutics (1766140) Subject | Form SCHEDULE 13G | |
| 07/08/2026 4:51 PM | INTEGRATED CORE STRATEGIES (0) US Unicycive Therapeutics (1766140) Subject | Form SCHEDULE 13G/A | |
Get the Latest News and Ratings for UNCY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Unicycive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 07/02/2026 9:30 AM | Unicycive Therapeutics (1766140) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/01/2026 4:48 PM | Unicycive Therapeutics (1766140) Subject Vivo Opportunity Fund Holdings, L.P. (1930214) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/22/2026 5:05 AM | Unicycive Therapeutics (1766140) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/22/2026 5:07 AM | Unicycive Therapeutics (1766140) Filer | Form DEFA14A | |
| 06/15/2026 11:15 PM | Unicycive Therapeutics (1766140) Filer | Form EFFECT | |
| 06/15/2026 4:23 PM | Jermasek Douglas (1955273) Reporting Unicycive Therapeutics (1766140) Issuer | Form 4/A | |
| 06/15/2026 4:23 PM | Townsend John (1511906) Reporting Unicycive Therapeutics (1766140) Issuer | Form 4/A | |
| 06/15/2026 4:24 PM | Gupta Pramod (1857927) Reporting Unicycive Therapeutics (1766140) Issuer | Form 4/A | |
| 06/15/2026 4:24 PM | Laumas Sandeep (1721664) Reporting Unicycive Therapeutics (1766140) Issuer | Form 4/A | |
| 06/15/2026 4:24 PM | Kenkare-Mitra Sara (1895592) Reporting Unicycive Therapeutics (1766140) Issuer | Form 4/A | |
| 06/15/2026 4:24 PM | Gupta Shalabh K. (1864917) Reporting Unicycive Therapeutics (1766140) Issuer | Form 4/A | |
| 06/05/2026 3:15 PM | Unicycive Therapeutics (1766140) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 06/05/2026 3:19 PM | Unicycive Therapeutics (1766140) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/21/2026 3:30 PM | Kenkare-Mitra Sara (1895592) Reporting Unicycive Therapeutics (1766140) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/21/2026 3:30 PM | Gupta Shalabh K. (1864917) Reporting Unicycive Therapeutics (1766140) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/20/2026 3:30 PM | Townsend John (1511906) Reporting Unicycive Therapeutics (1766140) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/20/2026 3:30 PM | Gupta Pramod (1857927) Reporting Unicycive Therapeutics (1766140) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/20/2026 3:30 PM | Jermasek Douglas (1955273) Reporting Unicycive Therapeutics (1766140) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/18/2026 7:57 PM | Laumas Sandeep (1721664) Reporting Unicycive Therapeutics (1766140) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/15/2026 3:45 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Unicycive Therapeutics (1766140) Subject | Form SCHEDULE 13G/A | |
| 05/12/2026 6:51 AM | Unicycive Therapeutics (1766140) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/12/2026 5:30 AM | Unicycive Therapeutics (1766140) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/05/2026 8:02 PM | Unicycive Therapeutics (1766140) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 04/30/2026 6:00 AM | Unicycive Therapeutics (1766140) Filer | Form DEF 14A | |
| 04/30/2026 6:02 AM | Unicycive Therapeutics (1766140) Filer | Form DEFA14A | |
| 04/30/2026 6:04 AM | Unicycive Therapeutics (1766140) Filer | Form ARS | |
| 04/06/2026 8:11 AM | Unicycive Therapeutics (1766140) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/30/2026 6:29 AM | Unicycive Therapeutics (1766140) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/30/2026 5:32 AM | Unicycive Therapeutics (1766140) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/17/2026 3:45 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Unicycive Therapeutics (1766140) Subject | Form SCHEDULE 13G/A | |
Your Copy is on Hold (Claim it now) (Ad) James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play.
He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60.
Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date. Claim your copy of James Altucher's new Elon Musk report today. |
| 02/10/2026 12:15 PM | Octagon Capital Advisors LP (1839435) Filed by Unicycive Therapeutics (1766140) Subject | Form SCHEDULE 13G/A | |
| 01/23/2026 3:41 PM | INTEGRATED CORE STRATEGIES (0) US Unicycive Therapeutics (1766140) Subject | Form SCHEDULE 13G | |